✦ LIBER ✦

T1124 Once Daily 3g Mesalamine Is the Optimal Dose for Maintaining Clinical Remission in Ulcerative Colitis: A Double-Blind, Double-Dummy, Randomized, Controlled, Dose-Ranging Study

✍ Scribed by Kruis, Wolfgang; Jonaitis, Laimas; Pokrotnieks, Juris; Acute, Gitana; Mikhailova, Tatyana L.; Horynski, Marek; Bátovský, Marian; Rácz, István; Kull, Karin; Faszczyk, Mark; Greinwald, Roland; Mueller, Ralph

Book ID: 123110332
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 101 KB
Volume: 134
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(08)62285-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P206 - Which patient population profits

P206 - Which patient population profits best from a high dose, once daily treatment with 3.0g mesalazine for maintaining clinical remission in ulcerative colitis? A subgroup analysis of a double-blind, double-dummy, randomised, controlled, dose-ranging study

✍ W. Kruis; L. Jonaitis; L. Kupcinskas; J. Pokrotnieks; G. Acute; T.L. Mikhailova; 📂 Article 📅 2009 🏛 Oxford University Press 🌐 English ⚖ 51 KB

Tu1122 Optimal Dosing of Mesalamine for

Tu1122 Optimal Dosing of Mesalamine for Maintenance of Clinical Remission in Patients With Distal Ulcerative Colitis and Residual Endoscopic Activity: A Subgroup Analysis of a Double-Blind, Double-Dummy, Randomized, Controlled, Dose-Ranging Study

✍ Kruis, Wolfgang; Greinwald, Roland; Mueller, Ralph 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 246 KB